Available online **www.ijpras.com**

International Journal of Pharmaceutical Research & Allied Sciences, 2026, 15(4):162-172

https://doi.org/10.51847/Wj1zAspVTI

Original Article

ISSN : 2277-3657
CODEN(USA) : IJPRPM

The Gut Microbiome as a Transferability Condition in Pharmaceutical Development: A Translational Framework for Microbial Drug Transformation, Community Function, and Cross-Population Response Differences

Julia Weber[1]*, Nadia Benali[2], Thomas Mwangi[3], Hassan Al-Rashid[4]

[1]Department of Pharmaceutical Biotechnology, Free University of Berlin, Berlin, Germany.
[2]Department of Clinical Pharmacology, University of Tunis El Manar, Tunis, Tunisia.
[3]Department of Pharmaceutical Sciences, University of Nairobi, Nairobi, Kenya.
[4]Department of Pharmaceutical Sciences, King Fahd University of Petroleum and Minerals, Dhahran, Saudi Arabia.

***Email:** julia.weber@fu-berlin.de*

ABSTRACT

Microbial metabolism can alter a medicine before absorption, yet evidence that a gut community interacts with a drug is frequently extended beyond the biological system in which that interaction was observed. This original comparative translational analysis examines when microbiome-linked findings can be carried from isolates, ex-vivo consortia or animal models to clinical populations. It distinguishes microbial taxonomic composition, biochemical transformation of drug molecules, sequestration of intact drug, ecological and host-signalling effects, systemic exposure and therapeutic response. Evidence from molecular mapping, community-function experiments, physiological studies and selected clinical investigations motivates a conditional account: a mechanism can support cross-population pharmaceutical inference only when its relevant substrate, active microbial function, luminal context, host interface and endpoint are sufficiently comparable for the proposed claim. The conditions differ for drug disposition and microbiome-mediated pharmacodynamics. This account generates discriminating tests involving matched chemical mass balance, functional perturbation, intestinal exposure and clinical pharmacokinetic or pharmacodynamic measurements. Its claims remain theoretical where direct human validation is absent. Treating transferability as a drug–mechanism–context-specific property may improve experimental model selection and prevent microbiome associations from being mistaken for established clinical drug effects.

Key words: *Gut microbiome, Microbial xenobiotic metabolism, Pharmaceutical transferability, Microbiome-derived drug metabolites, Functional community comparability, Host–microbiome pharmacology*

Received: 15 August 2026; **Revised:** 18 September 2026; **Accepted:** 23 September 2026

INTRODUCTION

The gut microbiome enters pharmaceutical research through several distinct routes. Bacteria may chemically modify an administered compound, change its local availability, respond ecologically to the compound, or modify host pathways that influence treatment. These observations matter for pharmacology, but each supports a different inference. Contemporary integrative pharmacology recognizes that microbial activities can become determinants of drug disposition and action without assuming a universal microbiome effect for every medication [1]. The

© 2026 The International Journal of Pharmaceutical Research and Allied Sciences (IJPRAS). **Open Access** - This article is under the **CC BY NC SA** license (https://creativecommons.org/licenses/by-nc-sa/4.0).

translational question is narrower and more demanding: which features of an interaction must persist when an experimental finding is applied to another patient group or biological system?

Variation in drug response has motivated a broader concept of *pharmaecology* in which drugs, microbes and the host participate in changing exposures and physiological states [2]. Personalized-medicine reviews likewise describe opportunities to use microbial signatures therapeutically while documenting the obstacles to clinical prediction and intervention [3]. The presence of a microbial association cannot establish whether the organisms transformed the parent compound, altered an endogenous metabolite, changed an immune pathway, or merely tracked a background determinant of treatment response.

Pharmaceutical comparisons also occur across environmental conditions that are seldom reproduced in the same assay. Repeated human sampling links intestinal transit, pH and stool characteristics to intra-individual changes in community composition and metabolism [4]. A static fecal culture therefore may reproduce one measurable activity while failing to represent the intestinal site and residence time relevant to a drug. This article develops comparative rules for identifying that partial match, evaluating rival mechanisms, and deciding the level at which a claim can move between systems. It is a theoretical synthesis of published findings, with no new clinical or laboratory dataset and no claimed validation of a predictive tool.

Microbiome variability as a challenge to pharmaceutical transferability

A microbiome description can be stable at one analytical level and variable at another. Gut biogeography creates differences between mucosal and luminal habitats, intestinal regions and fecal sampling; the community obtained in stool is a convenient observation of a spatially structured system [5]. The relevant comparison for an orally administered drug is consequently the community activity at the location and time of drug contact, which may be neither the average fecal taxonomic profile nor the maximum conversion capacity of an isolate.

Intestinal pH modifies microbial environments and metabolic activity, while potentially changing drug ionization, dissolution or availability independently of microbial action [6]. Transit duration can similarly influence the amount of time available for chemical conversion, host absorption and community growth. Functional comparability, as used here, means demonstrated correspondence in a specified drug-relevant microbial process under pertinent exposure conditions; it cannot be inferred from overall species overlap alone. That definition requires a named substrate or host mediator, a measurable endpoint and an explicit model of the environment in which the endpoint arises.

Strain resolution adds a second constraint. Cross-cohort metagenomic work on type 2 diabetes has identified strain-specific microbial associations, illustrating why genus-level signals can hide meaningful biological variation [7]. Human host genetics can also associate with gut microbial structural variation [8]. Neither result demonstrates that a named microbial variant metabolizes a particular pharmaceutical agent. Their relevance is to the *resolution of a transfer claim*: a function cannot be transported on the basis of a taxonomic label unless the functional determinant is conserved and operative in both settings.

Even the idea of a universally healthy community is contested because ecological diversity varies across populations and contexts [9]. A pharmaceutical comparator should therefore be defined by the drug mechanism under examination. For a microbial reductase it may be local enzyme activity and substrate access; for drug-driven community disruption, it may be ecological resilience and competing growth opportunities. Population-average similarity may be informative for sampling but cannot serve as a surrogate for matched exposure or patient response.

Current evidence on microbial drug transformation and host–microbiome interactions

Direct microbial transformation requires evidence that the parent molecule acquires a different chemical identity. Systematic work with human gut isolates mapped numerous transformations and associated them with bacterial genetic determinants [10]. Personalized ex-vivo screens subsequently demonstrated variable drug-metabolizing activities among human-derived communities [11]. The stronger claim supported by these studies concerns metabolic *capacity under tested conditions*. The clinical consequence depends additionally on whether the relevant drug reaches that community at an active concentration before absorption, whether the product crosses the gut barrier, and whether host clearance or alternative reactions dominate.

The interspecies bacterial pathway described for levodopa illustrates how a mechanism becomes more discriminating when its intermediates and microbial participants are identified and inhibition is experimentally examined [12]. It also illustrates a transfer problem: reducing a pathway in an experimental system is not equivalent to showing a predictable adjustment in clinical dose requirements across populations. A distinct

phenomenon is intact-drug bioaccumulation in gut bacteria. Chemical depletion from medium may reflect cellular uptake without covalent transformation [13]; the pharmaceutical interpretation then turns on binding, retention and possible release, with different implications for mass balance and intestinal exposure.

Chemical products can change pharmacological activity. Experiments with G-protein-coupled-receptor-targeted drugs connected microbiota-derived transformation products with altered activity in tested receptor systems [14]. A receptor assay identifies a potentially relevant chemical change but does not establish systemic concentrations, tissue selectivity or human therapeutic benefit. Drug–microbe interaction is also reciprocal: transformation of dietary xenobiotics can reshape microbial community composition through toxification or detoxification mechanisms [15]. These ecological responses may alter a later drug exposure history, yet dietary compounds are not automatically interchangeable with prescription medicines.

Community function may change even when drug metabolism has not been shown. Ex-vivo metaproteomics has documented medication-associated shifts in microbial proteins and functional states [16]. Selection for xenobiotic-associated functions under environmental exposure provides another route to altered functional capacity [17]. Finally, screening of non-antibiotic medicines found direct effects on bacterial growth [18]. These studies support the need to separate four observable endpoints: transformed chemical product, intracellular intact compound, changed microbial expression and changed community ecology. **Table 1** distinguishes what each permits an investigator to infer about pharmaceutical exposure.

Table 1. Drug-contact observations distinguished by chemical fate, microbiological unit and admissible pharmaceutical inference

Drug-contact phenomenon	Experimental unit and observable	Mechanism established in cited literature	Conditional pharmaceutical inference	Critical unresolved comparison
Enzymatic conversion of parent compound	Isolates or ex-vivo consortia; identified chemical product	Microbial enzymes and community-dependent drug metabolism have been experimentally characterized	Parent-drug availability or metabolite activity may change if conversion occurs before relevant absorption	Intraluminal substrate delivery, product flux and clinical pharmacokinetics
Interspecies pathway conversion	Interacting bacterial partners; levodopa metabolic intermediates	Cooperative microbial reaction pathway and experimentally explored inhibition	Pathway inhibition may modify presystemic loss where both partners are active	Pathway persistence, substrate competition and patient-level dose–exposure link
Intact-drug sequestration	Bacterial cells; reduced extracellular parent without chemical modification	Intracellular accumulation of unchanged therapeutic compounds	Free luminal concentration may vary without formation of a new metabolite	Reversibility of uptake, release during transit and bioavailable fraction
Drug-derived alteration of bioactivity	Microbial product and pharmacological receptor assay	Transformation products can differ in activity against tested receptors	Changed receptor engagement is plausible at exposure-relevant concentrations	Human metabolite abundance, receptor access and endpoint concordance
Drug-perturbed functional or ecological state	Mixed community; proteome, growth or taxon abundance	Medicines can alter microbial proteins and bacterial fitness	Later drug processing or host signals may become context-dependent	Temporal ordering and demonstration of a named drug-processing reaction

Table note: Entries integrate reported experimental categories with conditional interpretations; they are not clinical effect estimates. Exact source-to-row provenance is retained in the approved evidence matrices. No numerical threshold for transferability has been validated.

Functional differences between experimental and clinical microbial communities

Experimental communities often provide excellent control over substrate concentration while deliberately removing the intestinal environment that shaped their donor. Computational prediction of drug–microbe interactions draws on compound properties and microbial genomic features, but its modeled target may be

bacterial susceptibility, not a metabolic product or patient outcome [19]. A prediction of microbiome perturbation must not be relabeled as a prediction of drug clearance.

The consequences of context loss are apparent in ecological experiments. Non-antibiotic drugs have reduced colonization resistance and enhanced enteropathogen growth in certain synthetic and stool-derived communities, with selected effects investigated in mice [20]. An independent investigation identified medication–microbiome interactions affecting gut infection [21]. These findings are important evidence of functional response to pharmaceuticals; they do not by themselves indicate that microbes chemically inactivate those medicines. Host inflammation, pathogen availability and resident-community competition determine whether an ecological effect travels to another setting.

Host–microbiome metabolic modeling in inflammatory bowel disease connects longitudinal molecular observations with reconstructed metabolic networks during advanced drug treatment [22]. Reconstruction can expose candidate exchanges, but the reaction network depends on its input measurements and modeling assumptions. An experimental culture with a detectable drug metabolite, a simulated metabolic exchange and a clinical patient with a changed treatment response therefore belong to three separate evidence classes. Their findings can reinforce each other only when the same process and its necessary environmental conditions are measured or independently constrained.

Time introduces an additional asymmetry. A single ex-vivo snapshot may miss drug-induced selection that gradually changes enzyme-bearing taxa or substrate competition. Conversely, a community observed after months of treatment may reflect disease activity, background medicines or adaptation, obscuring the original causal direction. A clinically informative comparison should jointly identify the model's preserved mechanism, omitted host inputs and the endpoint at which the claim ceases to be demonstrated. **Figure 1** maps these dependencies while keeping biological transport and evidence extrapolation visibly distinct.




Figure 1. Drug chemical fate, microbial functional state and host response form interacting but non-equivalent evidence pathways

***Figure 1** legend.* Intestinal drug contact has multiple possible fates: enzymatic conversion to a distinguishable product, reversible or persistent bacterial accumulation of intact compound, and changes in microbial ecological activity. Parent compound and microbial products may interact with host absorption or signaling; drug-driven ecological changes may also feed back to later microbial function. Solid arrows designate experimentally investigated relationships within relevant systems; dashed arrows represent conditional cross-level or clinical implications that require additional verification. The lower measurement band separates isolate, ex-vivo community, host-model and patient observations. A surrounding context band identifies exposure, intestinal pH,

transit and host state as conditions affecting interpretation. GPCR, G-protein-coupled receptor; PK, pharmacokinetics; PD, pharmacodynamics. No link is intended as an unreported patient-level effect size.

*Alt text—**Figure 1***. Wide, asymmetrical scientific map showing intestinal parent drug on the left, parallel upper transformation and lower intact-drug accumulation paths in the center, a drug-driven community ecological response below, and separate host exposure and response regions on the right. Solid connections identify investigated biochemical or ecological relationships; dashed links cross toward hypothesized patient pharmacokinetics and outcomes. Physiological modifiers occupy a band above the biological compartments, and a lower band separates four measurement contexts to prevent an assay observation being read as a demonstrated clinical result.

Unresolved questions in cross-population pharmaceutical interpretation

Clinical effects involving the microbiome may emerge without measurable microbial catabolism of the administered drug. In prediabetes, combined fermentable-carbohydrate dietary intervention and metformin was associated with altered microbiota and improved glycaemic control [23]. The combined intervention makes it inappropriate to assign the outcome to a single bacterial drug-transforming reaction. Earlier randomized treatment work in treatment-naive type 2 diabetes showed that metformin alters the microbiome and that transferred treatment-associated microbiota could affect glucose tolerance in a mouse model [24]. Fecal transfer strengthens a microbiome-contribution argument but does not specify that metformin molecules underwent bacterial conversion.

Mechanistic studies connecting microbiota, bile acids and intestinal farnesoid X receptor signaling to metformin benefits support a different explanatory route [25]. This host-signaling pathway may affect pharmacodynamics without equivalent changes in systemic parent-drug pharmacokinetics. Consequently, a comparison that tests only plasma drug concentration could miss a microbiome-conditioned response, while a comparison limited to fecal taxa could misattribute the effect to microbial metabolism. An appropriate rival analysis asks whether intestinal host regulation, diet, altered absorption or disease state explains the observation more economically than direct microbial catabolism.

Population-level ecological differences raise additional questions. Enterobacteriaceae dynamics across global human populations vary with ecological context [26]. These patterns warn against assuming universal community behavior, but no taxon-level geographic difference supplies a drug-specific transfer coefficient. The investigator must establish whether the relevant microbial gene is expressed, whether substrate exposure is comparable, and whether the hypothesized host link exists in the receiving population. **Table 2** distinguishes the kinds of population variation and the observation necessary to test whether they actually modify a pharmaceutical inference.

Table 2. Population differences that can preserve a microbial signature while changing its pharmaceutical meaning

Comparison axis	What may differ between populations or models	Measurement capable of discriminating mechanisms	Transfer error if unmeasured	Proposed comparator strategy
Microbial strain repertoire	Enzyme-bearing variants within apparently similar taxa	Strain-resolved functional gene and expressed activity	Treating genus overlap as matched metabolism	Compare conversion phenotype of matched substrates
Intestinal microenvironment	Regional pH, transit, nutrient availability and drug contact	Site-relevant exposure and physiological covariates	Equating fecal potential with presystemic reaction	Match or experimentally vary contact conditions
Drug and dietary history	Concurrent therapies and fermentable substrate availability	Repeated exposure and dietary documentation	Assigning an intervention mixture to one mechanism	Within-stratum and factorial comparisons where feasible
Host-mediated signaling	Bile-acid signaling, inflammatory state and epithelial response	Host-pathway markers alongside parent and metabolite PK	Calling altered PD microbial drug degradation	Test host mediator separately from chemical drug fate
Community resilience	Susceptibility to medication-induced ecological displacement	Longitudinal community function and drug-free recovery	Assuming a one-time culture response persists	Sample before, during and after perturbation

Geographic or clinical cohort composition	Strain distribution, disease, sampling and treatment differences	Harmonized design with prospective external replication	Reinterpreting cohort classification as patient-level causation	Separate context transport from outcome prediction

Table note: The last column sets out proposed study designs, not established validation criteria. PK indicates pharmacokinetics; PD indicates pharmacodynamics. Geographic variability and microbiome shifts have no assumed direction of drug efficacy.

Development of the proposed microbiome-conditioned transferability framework

The proposed contribution treats transferability as a relation among a specified medicine, a specified microbial or host–microbial mechanism, a source experimental system, a recipient population, and a claim endpoint. It is deliberately not an intrinsic property of a taxon or a global score for microbiome similarity. The first comparison establishes *chemical identity*: is a measurable reaction product formed, does unchanged compound accumulate, or is the intervention altering a host mediator without modifying the medicine? Reaction-network computational methods can prioritize candidate microbiota-dependent conversions [27], but a feasible predicted pathway remains a hypothesis until actual products and reactions have been characterized under relevant conditions.

The second comparison concerns *functional operation*: the required enzymes or interaction partners must be present, active and accessible to substrate in both source and recipient contexts. The third concerns *exposure opportunity*: formulation, dose location, luminal chemistry, residence time and host absorption must allow the same process to influence the drug fraction at issue. A fourth comparison determines *endpoint continuity*: microbiological chemistry may support a claim about a product, whereas a claim about plasma drug exposure requires pharmacokinetic linkage and a therapeutic claim requires clinically pertinent response measurements. Passing an earlier comparison never substitutes for observing the next level.

Different drug classes require different chains of evidence. Immunotherapy studies associating microbial communities and metabolites with response—including work implicating microbial metabolites in anti-PD-1 treatment modulation—demonstrate a possible host-immune route [28]. Such findings do not indicate that intestinal bacteria biotransform therapeutic antibodies. This contrast prevents a chemically grounded small-molecule mechanism from becoming an unsuitable default explanation for host-mediated effects of biologics.

Figure 2 operationalizes the comparisons as a branching *cross-population claim network*. Concordance of substrate chemistry and microbial activity can justify further testing of exposure; discordance can restrict a claim to its original assay without refuting the local finding. If a host-mediated mechanism explains a clinical association, the chemical-transformation branch may be irrelevant and a host-signaling comparator becomes necessary. The framework predicts a discriminating result: matched fecal taxonomic signatures with discordant functional reaction rates or intestinal exposure will not reliably reproduce a parent-drug pharmacokinetic effect. Conversely, a reproducible host mediator with no microbial transformation may support a pharmacodynamic hypothesis while leaving the parent-drug metabolism claim unsupported. These are proposals for empirical testing, not validated classification rules.




Figure 2. Cross-population drug-response claims depend on mechanism-matched comparisons, not community resemblance alone

***Figure 2** legend.* Source experimental and recipient clinical systems are connected through parallel comparisons of chemical fate, microbial functional operation, intestinal exposure opportunity, host-pathway participation and endpoint continuity. Solid links represent directly assessable comparisons; dashed links represent the proposed condition that a claim at one biological level can support a claim at another only with relevant measurements. Branching interpretations distinguish supported mechanism-level transport, a restricted assay-only conclusion and alternative host-mediated explanation. No numerical cutoff or universal set of sufficient conditions is asserted. PK, pharmacokinetics; PD, pharmacodynamics; GPCR, G-protein-coupled receptor.
*Alt text—**Figure 2**.* Wide network with a source experimental community to the left and a receiving clinical population to the right. Between them, multiple non-identical comparison modules evaluate chemical substrate and product identity, active microbial function, local exposure conditions, host-mediated routes and concordance of clinical endpoint. The upper path supports conditional further testing; branching side paths identify chemical non-match, functional non-match and a separate host-signaling explanation. Solid arrows show comparisons; dashed arrows show proposed translational inferences; a bottom inference band separates assay, exposure and therapeutic claims.

Implications for preclinical research, clinical development, and drug evaluation

Preclinical development should specify the consequential chemical or host-pathway event before selecting a model. For a candidate susceptible to bacterial conversion, experiments can measure parent disappearance together with chemically identified products, cell-associated intact compound and recovery after release. Comparing fractions across isolates and donor communities identifies biochemical fate; physiologically plausible drug contact and residence conditions test possible effects on absorbed exposure. For a therapeutic whose microbiome association arises through immune regulation, a metabolite–host-signaling assay is more relevant than an arbitrary test for catabolism of the medicine itself.

Clinical development then faces a different sampling problem. Baseline fecal profiles alone are poor substitutes for within-patient exposure histories, co-medication records and paired host measurements. The growing oncology literature evaluates microbiome-targeted strategies alongside immune checkpoint therapy, but repeatedly identifies challenges of intervention reproducibility, patient selection and interpretation of clinical efficacy [29]. Microbiota-derived short-chain fatty acids, bile acids and tryptophan metabolites can influence immune pathways in context-dependent ways [30]. Their plausible immunological activity supports pathway-focused development; it does not establish a common metabolite threshold applicable across cancers, therapies or patient populations.

Drug evaluation can distinguish three questions: whether a microbial process exists under test conditions, whether it modifies biologically relevant exposure or host signaling, and whether manipulating that process changes a therapeutic or safety endpoint. Each additional question requires its own comparator. Where clinical translation is pursued, prespecified negative results should remain informative: unchanged parent and metabolite pharmacokinetics following an effective functional perturbation would challenge a proposed drug-disposition mechanism even if community composition changed.

Testable transferability conditions and evidence requirements

For direct catabolism, compare chemically resolved parent–product mass balance across exposure conditions, followed by suppression or enhancement of the implicated microbial function. If the putative product is found only in enriched culture, the defensible result is culture-dependent capability. In contrast, finding comparable in-vivo product exposure with an independently measured microbial reaction strengthens transport of the chemical mechanism. A clinical-response claim additionally requires an endpoint with an appropriate causal design.

For sequestration, unchanged parent drug within microbial cells and its release kinetics matter more than the appearance of a novel metabolite. For host-mediated pharmacodynamics, it is necessary to examine microbial mediator abundance, host pathway engagement and treatment response while testing nonmicrobial alternatives. Ecological interventions add a persistence requirement: functional similarity at baseline may not persist after colonization, dietary change or drug-induced selection. Strain-tracking after fecal microbiota transplantation demonstrates that engraftment dynamics can depend on donor, recipient and microbial context [31]; it supplies a

reason to test temporal persistence, not evidence that microbiome transplantation produces a predictable pharmaceutical effect for every drug.

These comparisons create falsifiable predictions. A genetic marker that predicts a reaction in one donor but shows no corresponding biochemical flux in recipients fails a function-level transfer test. A shared microbial product accompanied by divergent host exposure limits a disposition inference. A therapeutic association persisting after an experimentally effective elimination of the nominated microbial pathway would favor a rival explanation. **Table 3** specifies the paired observations and counterfactual contrasts that would separate these conclusions without a universal pass threshold.

Table 3. Mechanism-specific paired tests for evaluating the level at which microbiome findings can transfer

Pharmaceutical claim under test	Source-to-recipient evidence pair	Discriminating perturbation or contrast	Rival process requiring separation	Permitted level of inference
Presystemic chemical conversion of parent drug	Identical substrate and structurally confirmed product; matched luminal exposure	Inhibit or remove implicated bacterial activity; assay product flux	Host metabolism, abiotic degradation, adsorption	Chemical-mechanism transfer only until in-vivo exposure is demonstrated
Bacterial accumulation of intact medicine	Extracellular depletion plus intracellular recovery of unchanged compound	Measure retention and release during changing contact conditions	Enzyme-mediated conversion or precipitation	Sequestration mechanism, with bioavailability consequences still conditional
Metabolite-driven pharmacological change	Verified molecular product and relevant receptor or host-pathway readout	Compare product exposure and pathway blockade	Other microbial mediators or direct drug action	Mechanistic activity; clinical response requires an additional study
Host-immune effect during treatment	Microbial mediators, host immune state and drug-specific clinical endpoint	Intervention with matched therapy and competing clinical factors	Disease severity, antibiotics, diet, anticancer co-treatment	Context-bounded pharmacodynamic hypothesis until causally evaluated
Persistent community-mediated effect	Longitudinal strain/function measurements before and after perturbation	Repeated follow-up against unperturbed control	Ecological drift, failure to engraft, co-medication changes	Temporally restricted function transfer if the measured effect persists

Table note: Each row is an original proposed comparison, not a validated clinical decision algorithm. Inference remains limited to the outcome actually observed. No universal equivalence margin, dose threshold or prediction accuracy is asserted. Table provenance is retained in the approved evidence matrices; the visible table contains no numbered citations.

Discussion, biological diversity, and future research

Population differences can enter a pharmaceutical explanation at multiple points. Strain identity may change the availability of an enzyme; intestinal environment may alter its activity; formulation and absorption may restrict substrate contact; host physiology may change the concentration or consequences of a metabolite. These sources of variation need not move together. Thus apparent taxonomic convergence across cohorts can coexist with different drug-relevant flux, while taxonomically divergent communities might deliver functionally similar reactions under matched conditions.

Observational research also faces medication confounding. Associations between drugs and the microbiome can be combinatorial, additive and dose-dependent, making single-agent interpretations hazardous when patients receive complex regimens [32]. A next generation of comparisons should therefore prioritize within-person time courses, explicit medication histories, appropriate negative controls, geographically distinct recipient cohorts and mechanistically distinct drug classes. Null findings can delimit a transfer claim: a reproducible microbial reaction may be irrelevant to systemic dose when the medicine is absorbed before reaching the active community. Conversely, host-immune modulation may retain therapeutic relevance despite no bacterial modification of the administered biologic.

The strongest future test is not whether a microbiome-based classifier predicts a response inside its development cohort. It is whether the nominated microbial function, its material or signaling consequence and the patient endpoint survive deliberate changes in population and environment while plausible alternatives are measured.

Success at one level should narrow the next experiment; failure should specify which linkage could not be transported.

Limitations and translational boundaries

This is an evidence-bounded theoretical synthesis and offers neither a systematic-search estimate of the literature nor a quantitatively validated transfer algorithm. The approved source set combines bacterial isolates, ex-vivo communities, animal work, computational analysis, association studies and clinical investigations. Evidence quality and endpoint validity are consequently heterogeneous. A reported reaction in culture cannot establish its magnitude in the intestine; a fecal metabolite concentration cannot uniquely identify microbial origin, compartment or tissue exposure; and a clinical association cannot isolate microbiome causality without suitable intervention and controls.

The account is most directly applicable when the relevant drug, metabolite or host mediator can be measured with sufficient specificity. Where the operative mediator is unknown, the comparisons serve as hypotheses for method development. A claim may also be weakened by poorly represented intestinal compartments, unrecorded treatment histories, sparse sampling or ecological adaptation after intervention. Neither an absent fecal signal nor a discordant taxonomic profile necessarily proves the absence of a locally active mechanism.

CONCLUSION

Microbiome-conditioned pharmaceutical transferability depends on correspondence in the drug-relevant function and the biological circumstances under which it can matter. Microbial chemical conversion, intact-drug sequestration, ecological remodeling and host-mediated therapeutic effects require different measurements and different causal comparisons. A finding may transfer as a biochemical capability while remaining unproven as a change in human exposure or clinical response. Mechanism-specific, population-paired experiments offer a practical way to define that distinction and to challenge it through falsifiable alternatives.

ACKNOWLEDGMENTS: None

CONFLICT OF INTEREST: None

FINANCIAL SUPPORT: None

ETHICS STATEMENT: None

REFERENCES

1. Verdegaal AA, Goodman AL. Integrating the gut microbiome and pharmacology. Sci Transl Med. 2024;16(732):eadg8357. doi:10.1126/scitranslmed.adg8357
2. Trepka KR, Olson CA, Upadhyay V, Zhang C, Turnbaugh PJ. Pharma[e]cology: How the gut microbiome contributes to variations in drug response. Annu Rev Pharmacol Toxicol. 2025;65(1):355-73. doi:10.1146/annurev-pharmtox-022724-100847
3. Ratiner K, Ciocan D, Abdeen SK, Elinav E. Utilization of the microbiome in personalized medicine. Nat Rev Microbiol. 2024;22(5):291-308. doi:10.1038/s41579-023-00998-9
4. Procházková N, Laursen MF, La Barbera G, Tsekitsidi E, Jørgensen MS, Rasmussen MA, et al. Gut physiology and environment explain variations in human gut microbiome composition and metabolism. Nat Microbiol. 2024;9(12):3210-25. doi:10.1038/s41564-024-01856-x
5. McCallum G, Tropini C. The gut microbiota and its biogeography. Nat Rev Microbiol. 2024;22(2):105-18. doi:10.1038/s41579-023-00969-0
6. Brinck JE, Sinha AK, Laursen MF, Dragsted LO, Raes J, Vazquez Uribe R, et al. Intestinal pH: a major driver of human gut microbiota composition and metabolism. Nat Rev Gastroenterol Hepatol. 2025;22(9):639-56. doi:10.1038/s41575-025-01092-6
7. Mei Z, Wang F, Bhosle A, Dong D, Mehta R, Ghazi A, et al. Strain-specific gut microbial signatures in type 2 diabetes identified in a cross-cohort analysis of 8,117 metagenomes. Nat Med. 2024;30(8):2265-76. doi:10.1038/s41591-024-03067-7

8. Zhernakova DV, Wang D, Liu L, Andreu-Sánchez S, Zhang Y, Ruiz-Moreno AJ, et al. Host genetic regulation of human gut microbial structural variation. Nature. 2024;625(7996):813-21. doi:10.1038/s41586-023-06893-w
9. Joos R, Boucher K, Lavelle A, Arumugam M, Blaser MJ, Claesson MJ, et al. Examining the healthy human microbiome concept. Nat Rev Microbiol. 2025;23(3):192-205. doi:10.1038/s41579-024-01107-0
10. Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019;570(7762):462-7. doi:10.1038/s41586-019-1291-3
11. Javdan B, Lopez JG, Chankhamjon P, Lee YCJ, Hull R, Wu Q, et al. Personalized mapping of drug metabolism by the human gut microbiome. Cell. 2020;181(7):1661-79.e22. doi:10.1016/j.cell.2020.05.001
12. Rekdal VM, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP. Discovery and inhibition of an interspecies gut bacterial pathway for levodopa metabolism. Science. 2019;364(6445):eaau6323. doi:10.1126/science.aau6323
13. Klünemann M, Andrejev S, Blasche S, Mateus A, Phapale P, Devendran S, et al. Bioaccumulation of therapeutic drugs by human gut bacteria. Nature. 2021;597(7877):533-8. doi:10.1038/s41586-021-03891-8
14. Wu Q, Song D, Zhao Y, Verdegaal AA, Turocy T, Duncan-Lowey B, et al. Activity of GPCR-targeted drugs influenced by human gut microbiota metabolism. Nat Chem. 2025;17(6):808-21. doi:10.1038/s41557-025-01789-w
15. Culp EJ, Nelson NT, Verdegaal AA, Goodman AL. Microbial transformation of dietary xenobiotics shapes gut microbiome composition. Cell. 2024;187(22):6327-45.e20. doi:10.1016/j.cell.2024.08.038
16. Li L, Simopoulos CMA, Mayne J, Ning Z, Zhang X, Hamada M, et al. Systematic metaproteomics mapping reveals functional and ecological landscapes of ex vivo human gut microbiota responses to therapeutic drugs. Nat Commun. 2025;16(1):9383. doi:10.1038/s41467-025-64433-8
17. De Filippis F, Valentino V, Sequino G, Borriello G, Riccardi MG, Pierri B, et al. Exposure to environmental pollutants selects for xenobiotic-degrading functions in the human gut microbiome. Nat Commun. 2024;15(1):4482. doi:10.1038/s41467-024-48739-7
18. Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555(7698):623-8. doi:10.1038/nature25979
19. Algavi YM, Borenstein E. A data-driven approach for predicting the impact of drugs on the human microbiome. Nat Commun. 2023;14(1):3614. doi:10.1038/s41467-023-39264-0
20. Grießhammer A, de la Cuesta-Zuluaga J, Müller P, Gekeler C, Homolak J, Chang H, et al. Non-antibiotics disrupt colonization resistance against enteropathogens. Nature. 2025;644(8076):497-505. doi:10.1038/s41586-025-09217-2
21. Kumar A, Sun R, Habib B, Deng T, Bencivenga-Barry NA, Palm NW, et al. Identification of medication–microbiome interactions that affect gut infection. Nature. 2025;644(8076):506-15. doi:10.1038/s41586-025-09273-8
22. Taubenheim J, Kadibalban AS, Zimmermann J, Taubenheim C, Tran F, Schreiber S, et al. Metabolic modeling reveals a multi-level deregulation of host-microbiome metabolic networks in IBD. Nat Commun. 2025;16(1):5120. doi:10.1038/s41467-025-60233-2
23. Chu NHS, Ling J, Poon EWM, Lee JYS, Song Q, Zuo Z, et al. Combining a diet rich in fermentable carbohydrates with metformin improves glycaemic control and reshapes the gut microbiota in people with prediabetes. Nat Metab. 2025;7(8):1614-29. doi:10.1038/s42255-025-01336-4
24. Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23(7):850-8. doi:10.1038/nm.4345
25. Sun L, Xie C, Wang G, Wu Y, Wu Q, Wang X, et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med. 2018;24(12):1919-29. doi:10.1038/s41591-018-0222-4
26. Yin Q, da Silva AC, Zorrilla F, Almeida AS, Patil KR, Almeida A. Ecological dynamics of Enterobacteriaceae in the human gut microbiome across global populations. Nat Microbiol. 2025;10(2):541-53. doi:10.1038/s41564-024-01912-6
27. Chum S, Naveira Montalvo A, Hassoun S. Computational analysis of the gut microbiota-mediated drug metabolism. Comput Struct Biotechnol J. 2025;27:1472-81. doi:10.1016/j.csbj.2025.03.016

28. Zhu X, Hu M, Huang X, Li L, Lin X, Shao X, et al. Interplay between gut microbial communities and metabolites modulates pan-cancer immunotherapy responses. Cell Metab. 2025;37(4):806-23.e6. doi:10.1016/j.cmet.2024.12.013
29. Elkrief A, Pidgeon R, Maleki Vareki S, Messaoudene M, Castagner B, Routy B. The gut microbiome as a target in cancer immunotherapy: Opportunities and challenges for drug development. Nat Rev Drug Discov. 2025;24(9):685-704. doi:10.1038/s41573-025-01211-7
30. Perl M, Fante MA, Herfeld K, Scherer JN, Poeck H, Orberg ET. Microbiota-derived metabolites: Key modulators of cancer immunotherapies. Med. 2025;6(8):100773. doi:10.1016/j.medj.2025.100773
31. Schmidt TSB, Li SS, Maistrenko OM, Akanni W, Coelho LP, Dolai S, et al. Drivers and determinants of strain dynamics following fecal microbiota transplantation. Nat Med. 2022;28(9):1902-12. doi:10.1038/s41591-022-01913-0
32. Forslund SK, Chakaroun R, Zimmermann-Kogadeeva M, Markó L, Aron-Wisnewsky J, Nielsen T, et al. Combinatorial, additive and dose-dependent drug–microbiome associations. Nature. 2021;600(7889):500-5. doi:10.1038/s41586-021-04177-9